Drugs that contain Dexamethasone

1. List of Dextenza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254267 OCULAR THERAPEUTIX Composite hydrogel drug delivery systems
Sep, 2024

(1 year, 7 months from now)

US8563027 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs
Feb, 2030

(7 years from now)

US8409606 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs
May, 2030

(7 years from now)

US11458041 OCULAR THERAPEUTIX Punctal plug and bioadhesives
Nov, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 7, 2024

Market Authorisation Date: 30 November, 2018

Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery; Treatment of ocular itching associated with allergic conjunctivitis; Treatment of ocular inflammation and pain following ophthalmic surgery

Dosage: INSERT;OPHTHALMIC

More Information on Dosage

2. List of Dexycu Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560120 EYEPOINT PHARMS Vehicles for delivery of biologically active substances
Sep, 2022

(4 months ago)

US6960346 EYEPOINT PHARMS Vehicles for delivery of biologically active substances
Jul, 2023

(4 months from now)

US10799642 EYEPOINT PHARMS Dose guides for injection syringe
May, 2032

(9 years from now)

US10028965 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation
May, 2034

(11 years from now)

US10159683 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation
May, 2034

(11 years from now)

US10022502 EYEPOINT PHARMS Dose guides for injection syringe
Jun, 2034

(11 years from now)

US11097061 EYEPOINT PHARMS Systems, kits and methods for loading and delivering a small volume dose from a syringe
Jun, 2039

(16 years from now)

Market Authorisation Date: 09 February, 2018

Treatment: Treatment of postoperative inflammation; A method of loading medication into a syringe and delivering the medication to a treatment site

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage

3. List of Hemady drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537585 DEXCEL PHARMA Compositions comprising dexamethasone
Dec, 2037

(14 years from now)

US11304961 DEXCEL PHARMA Compositions comprising dexamethasone
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 3, 2026

Market Authorisation Date: 03 October, 2019

Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product

Dosage: TABLET;ORAL

More Information on Dosage

4. List of Ozurdex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8506987 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(25 days ago)

US8034366 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(25 days ago)

US9192511 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(25 days ago)

US10076526 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(25 days ago)

US8034370 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(25 days ago)

US10702539 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(25 days ago)

US6899717 ALLERGAN Methods and apparatus for delivery of ocular implants
Nov, 2023

(8 months from now)

Market Authorisation Date: 17 June, 2009

Treatment: Treatment of macular edema; Treatment of uveitis; Treatment of diabetic macular edema; Treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); Treatment of non-infectious uveitis affecting the posterior segment of the eye; Delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex

Dosage: IMPLANT;INTRAVITREAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic